423 related articles for article (PubMed ID: 37391802)
1. Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer.
Chen X; Li Z; Liang M; Zhang Z; Zhu D; Lin B; Zhou R; Lu Y
World J Surg Oncol; 2023 Jun; 21(1):194. PubMed ID: 37391802
[TBL] [Abstract][Full Text] [Related]
2. Research and experimental verification on the mechanisms of cellular senescence in triple-negative breast cancer.
Cao T; Huang M; Huang X; Tang T
PeerJ; 2024; 12():e16935. PubMed ID: 38435998
[TBL] [Abstract][Full Text] [Related]
3. Novel biomarkers identified in triple-negative breast cancer through RNA-sequencing.
Chen YL; Wang K; Xie F; Zhuo ZL; Liu C; Yang Y; Wang S; Zhao XT
Clin Chim Acta; 2022 Jun; 531():302-308. PubMed ID: 35504321
[TBL] [Abstract][Full Text] [Related]
4. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer.
Guo S; Liu X; Zhang J; Huang Z; Ye P; Shi J; Stalin A; Wu C; Lu S; Zhang F; Gao Y; Jin Z; Tao X; Huang J; Zhai Y; Shi R; Guo F; Zhou W; Wu J
Comput Biol Med; 2023 Jul; 161():107066. PubMed ID: 37263064
[TBL] [Abstract][Full Text] [Related]
5. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
[TBL] [Abstract][Full Text] [Related]
6. Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis.
Ma J; Chen C; Liu S; Ji J; Wu D; Huang P; Wei D; Fan Z; Ren L
Cancer Gene Ther; 2022 Nov; 29(11):1578-1589. PubMed ID: 35474355
[TBL] [Abstract][Full Text] [Related]
7. Identification of a Gene Expression Signature to Predict the Risk of Early Recurrence and the Degree of Immune Cell Infiltration in Triple-negative Breast Cancer.
Sato K; Miura K; Tamori S; Akimoto K
Cancer Genomics Proteomics; 2024; 21(3):316-326. PubMed ID: 38670590
[TBL] [Abstract][Full Text] [Related]
8. Transcriptome-Based Network Analysis Unveils Eight Immune-Related Genes as Molecular Signatures in the Immunomodulatory Subtype of Triple-Negative Breast Cancer.
Zhang J; Wang L; Xu X; Li X; Guan W; Meng T; Xu G
Front Oncol; 2020; 10():1787. PubMed ID: 33042828
[No Abstract] [Full Text] [Related]
9. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.
Zhang J; Zhang M; Tian Q; Yang J
Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794
[TBL] [Abstract][Full Text] [Related]
10. Targeting lncRNA DDIT4-AS1 Sensitizes Triple Negative Breast Cancer to Chemotherapy via Suppressing of Autophagy.
Jiang T; Zhu J; Jiang S; Chen Z; Xu P; Gong R; Zhong C; Cheng Y; Sun X; Yi W; Yang J; Zhou W; Cheng Y
Adv Sci (Weinh); 2023 Jun; 10(17):e2207257. PubMed ID: 37096846
[TBL] [Abstract][Full Text] [Related]
11. Identification of prognostic biomarkers among ICAMs in the breast cancer microenvironment.
Chen H; Pu S; Mei N; Liu X; He J; Zhang H
Cancer Biomark; 2022; 35(4):379-393. PubMed ID: 36373309
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy.
Zaib T; Cheng K; Liu T; Mei R; Liu Q; Zhou X; He L; Rashid H; Xie Q; Khan H; Xu Y; Sun P; Wu J
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768478
[TBL] [Abstract][Full Text] [Related]
13. The Role of
Chu J; Tang S; Li T; Fan H
Front Biosci (Landmark Ed); 2024 Feb; 29(2):73. PubMed ID: 38420798
[TBL] [Abstract][Full Text] [Related]
14. The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer.
Yan Z; Zhong Z; Shi C; Feng M; Feng X; Liu T
Cancer Biol Ther; 2024 Dec; 25(1):2355705. PubMed ID: 38778753
[TBL] [Abstract][Full Text] [Related]
15. HSPA8 Is a New Biomarker of Triple Negative Breast Cancer Related to Prognosis and Immune Infiltration.
Ying B; Xu W; Nie Y; Li Y
Dis Markers; 2022; 2022():8446857. PubMed ID: 36452344
[TBL] [Abstract][Full Text] [Related]
16. Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis.
Zhai Q; Li H; Sun L; Yuan Y; Wang X
Breast Cancer; 2019 Nov; 26(6):784-791. PubMed ID: 31197620
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancer.
Lin F; Huang J; Zhu W; Jiang T; Guo J; Xia W; Chen M; Guo L; Deng W; Lin H
Front Immunol; 2023; 14():1218987. PubMed ID: 37575241
[TBL] [Abstract][Full Text] [Related]
18. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
[TBL] [Abstract][Full Text] [Related]
19. A novel fatty-acid metabolism-based classification for triple negative breast cancer.
Yang X; Tang W; He Y; An H; Wang J
Aging (Albany NY); 2023 Feb; 15(4):1177-1198. PubMed ID: 36880837
[TBL] [Abstract][Full Text] [Related]
20. Identification of key genes as potential biomarkers for triple‑negative breast cancer using integrating genomics analysis.
Zhong G; Lou W; Shen Q; Yu K; Zheng Y
Mol Med Rep; 2020 Feb; 21(2):557-566. PubMed ID: 31974598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
